Cytomegalovirus Reactivation Is Associated with Increased Risk of Late-Onset Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Study in the Current Era of Viral Load Monitoring

Biology of Blood and Marrow Transplantation

Volumn 23, Issue 11, 2017, Pages 1961-1967

  Yong, Michelle K ^a,b   Ananda Rajah, Michelle ^a,c   Cameron, Paul U ^a,b   Morrissey, C Orla ^a   Spencer, Andrew ^a   Ritchie, David ^b,d   Cheng, Allen C ^a   Lewin, Sharon R ^a,b   Slavin, Monica ^b,e,f  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c General Medical Unit   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY   (Australia)

Author keywords

Cytomegalovirus; Immunocompromised; Infection; Invasive aspergillosis; Invasive fungal infection; Transplantation

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; ITRACONAZOLE; MELPHALAN; METHOTREXATE; MYCOPHENOLATE MOFETIL; POSACONAZOLE; VIRUS DNA;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; COHORT ANALYSIS; CYTOMEGALOVIRUS; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); MYCOSIS; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC MYCOSIS; VIRUS LOAD; VIRUS REACTIVATION; AGED; ALLOTRANSPLANTATION; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MULTICENTER STUDY; PATHOGENICITY; PROCEDURES; TRANSPLANTATION CONDITIONING; VIROLOGY;

ADULT; AGED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD;

EID: 85029004469     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2017.07.025     Document Type: Article

References (33)

1. Tomblyn, M., Chiller, T., Einsele, H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 15 (2009), 1143–1238.
2. Kennedy, K.J., Daveson, K., Slavin, M.A., et al. Mucormycosis in Australia: contemporary epidemiology and outcomes. Clin Microbiol Infect 22 (2016), 775–781.
3. Ananda-Rajah, M.R., Cheng, A., Morrissey, C.O., et al. Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach. Antimicrob Agents Chemother 55 (2011), 1953–1960.
4. Marty, F.M., Ljungman, P., Papanicolaou, G.A., et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 11 (2011), 284–292.
5. Green, M.L., Leisenring, W., Xie, H., et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol 3 (2016), e119–e127.
6. Gentile, G., Antonelli, G., Interplay between β herpesviruses and fungal infections in transplant patients: from the bench to the bedside. Future Virol 10 (2015), 399–414.
7. Mikulska, M., Raiola, A.M., Bruno, B., et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant 44 (2009), 361–370.
8. Garcia-Vidal, C., Upton, A., Kirby, K.A., Marr, K.A., Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 47 (2008), 1041–1050.
9. Panackal, A.A., Li, H., Kontoyiannis, D.P., et al. Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin Infect Dis 50 (2010), 1588–1597.
10. Girmenia, C., Raiola, A.M., Piciocchi, A., et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant 20 (2014), 872–880.
11. Martino, R., Pinana, J.L., Parody, R., et al. Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT. Bone Marrow Transplant 44 (2009), 749–756.
12. Fukuda, T., Boeckh, M., Carter, R.A., et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 102 (2003), 827–833.
13. Slavin, M.A., Introduction to the updated Australian and New Zealand consensus guidelines for the use of antifungal agents in the haematology/oncology setting, 2008. Intern Med J 38 (2008), 457–467.
14. Morrissey, C.O., Chen, S.C., Sorrell, T.C., et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis 13 (2013), 519–528.
15. De Pauw, B., Walsh, T.J., Donnelly, J.P., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46 (2008), 1813–1821.
16. Ljungman, P., Boeckh, M., Hirsch, H.H., et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis 64 (2017), 87–91.
17. Broers, A.E., van Der Holt, R., van Esser, J.W., et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 95 (2000), 2240–2245.
18. Marr, K.A., Carter, R.A., Boeckh, M., Martin, P., Corey, L., Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100 (2002), 4358–4366.
19. Li, L., Wang, J., Zhang, W., Yang, J., Chen, L., Lv, S., Risk factors for invasive mold infections following allogeneic hematopoietic stem cell transplantation: a single center study of 190 recipients. Scand J Infect Dis 44 (2012), 100–107.
20. Gimenez, E., Solano, C., Nieto, J., et al. An investigation on the relationship between the occurrence of CMV DNAemia and the development of invasive aspergillosis in the allogeneic stem cell transplantation setting. J Med Virol 86 (2014), 568–575.
21. Leruez-Ville, M., Ouachee, M., Delarue, R., et al. Monitoring cytomegalovirus infection in adult and pediatric bone marrow transplant recipients by a real-time PCR assay performed with blood plasma. J Clin Microbiol 41 (2003), 2040–2046.
22. Thursky, K., Byrnes, G., Grigg, A., Szer, J., Slavin, M., Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 34 (2004), 115–121.
23. Venton, G., Crocchiolo, R., Furst, S., et al. Risk factors of Ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients. Clin Microbiol Infect 20 (2014), 160–166.
24. Freeman, R.B. Jr, The “indirect” effects of cytomegalovirus infection. Am J Transplant 9 (2009), 2453–2458.
25. Boeckh, M., Nichols, W.G., Immunosuppressive effects of beta-herpesviruses. Herpes 10 (2003), 12–16.
26. Frascaroli, G., Varani, S., Blankenhorn, N., et al. Human cytomegalovirus paralyzes macrophage motility through down-regulation of chemokine receptors, reorganization of the cytoskeleton, and release of macrophage migration inhibitory factor. J Immunol 182 (2009), 477–488.
27. Dagenais, T.R., Keller, N.P., Pathogenesis of Aspergillus fumigatus in invasive aspergillosis. Clin Microbiol Rev 22 (2009), 447–465.
28. Ahn, K., Angulo, A., Ghazal, P., Peterson, P.A., Yang, Y., Fruh, K., Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc Natl Acad Sci USA 93 (1996), 10990–10995.
29. Schmidt-Hieber, M., Labopin, M., Beelen, D., et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood 122 (2013), 3359–3364.
30. Ljungman, P., Brand, R., Hoek, J., et al. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European Group for Blood and Marrow Transplantation. Clin Infect Dis 59 (2014), 473–481.
31. Nichols, W.G., Corey, L., Gooley, T., Davis, C., Boeckh, M., High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 185 (2002), 273–282.
32. Bhutani, D., Dyson, G., Manasa, R., et al. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant 21 (2015), 159–164.
33. Grow, W.B., Moreb, J.S., Roque, D., et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 29 (2002), 15–19.